Forecast: Business Enterprise R&D Expenditure in Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations in China

The business enterprise R&D expenditure in the basic pharmaceutical products and preparations manufacturing sector in China is forecasted to grow from $25.14 billion in 2024 to $30.59 billion in 2028, measured in 2015 PPP values. This represents a consistent year-on-year growth, with increases of 5.5% from 2024 to 2025, and 5.2% from 2025 to 2026, reflecting a strong trend of investment in pharmaceutical R&D. The compound annual growth rate (CAGR) over these five years is approximately 5.01%, indicating a steady expansion in this sector.

Future trends to watch for include:

• Technological advancements and digital health may further drive R&D investment.
• Policy changes that could impact pharmaceutical research innovation and funding.
• Increased focus on biological products which may require additional R&D investment.
• Global collaborations and partnerships that might accelerate development.